Absence of Adnexal Features (AdnF) in Nodular Basal Cell Carcinoma (nBCC) Predicts Complete Histologic Clearance (CHC) after Intralesional (IL) Interferon-g (IFN-g)-Based Therapy Using a Replication-Deficient Adenoviral Vector (SP-002/ASN-00). Poster presented at American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, United States, June 2026.
McMillan, C. L. D., Muller, D. A., Fernando, G. J. P., Depelsenaire, A. C. I., Jayashi-Flores, C., Masterman, K.-A., Namjoshi, S., Vyas, K., Pascoe, D., Hickling, J., Wallace, S., Duijsings, D., Vink, J., Wheatley, A. K., Juno, J., Siller, G., & Forster, A. H. (2025). Booster immunisation with skin-patch-delivered unadjuvanted SARS-CoV-2 spike protein vaccine is safe and immunogenic in healthy adults. Vaccines, 14(1), 28. https://doi.org/10.3390/vaccines14010028
Forster, A., Witham, K., Surrao, L., Vyas, K., Murugappan, S., Depelsenaire, S., Way, K., Namjoshi, S., Knirsch, C., Hickling, J., Treasure, P., Wheatley, A., Juno, J., Tan, H.-X., Chaiken, R., Siller, G., & Sahai, N. (2025). A randomized controlled phase I clinical trial of a quadrivalent influenza vaccine administered with a high-density microarray patch. Vaccines. [Add Volume/Issue/Pages/DOI]
Davies, C., Baker, B., Berger, M. N., Knox, S. L., Mowbray, E., Stewart, B. G., Booy, R., Hacker, E., Marmol, A., Ross, C., Muller, D. A., Mortimore, A. M., Siller, G., Forster, A. H., & Skinner, S. R. (2025). Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over. Vaccine, 48(126699), 126699. https://doi.org/10.1016/j.vaccine.2024.126699
Baker, B., Hacker, E., Siller, G., Lee, M., Mursaliyev, N., & Forster, A. (2023). Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study. Human Vaccines & Immunotherapeutics, 19(1), 2189409. https://doi.org/10.1080/21645515.2023.2189409
Chong, S., Wong, H. Y., Althabteh, A., Cox, C., Stevenson, P. H., Brown, S., Griffin, A., Isbel, N., Siller, G., Soyer, H. P., Schaider, H., Roy, E., Campbell, S., Green, A. C., & Khosrotehrani, K. (2022). Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: A randomized, double-blind, placebo-controlled pilot trial. Journal of the American Academy of Dermatology, 87(5), 1163–1166. https://doi.org/10.1016/j.jaad.2022.02.039
Hamid, M., Kunde, L., & Siller, G. (2018). Unusual presentation of post-operative cutaneous breast cancer metastasis. Poster presented at ASM Australasian College of Dermatologists Conference.
Charlston, S., & Siller, G. (2018). Teledermatologist expert skin advice: A unique model of care for managing skin disorders and adverse drug reactions in hepatitis C patients. The Australasian Journal of Dermatology, 59(4), 315–317. https://doi.org/10.1111/ajd.12803
Finnane, A., Siller, G., Mujcic, R., & Soyer, H. P. (2016). The growth of a skin emergency teledermatology service from 2008 to 2014: Teledermatology service audit. The Australasian Journal of Dermatology, 57(1), 14–18. https://doi.org/10.1111/ajd.12411
Finnane, A., Siller, G., & Sawyer, P. (2015). Teledermatologists’ Management of Emergency Skin Conditions. Medical Journal of Australia, 203(7), 286.
Use of topical 5% imiquimod to treat superficial non-melanoma skin cancer in patients on TNF inhibitors for psoriasis. Presented at Australasian College of Dermatologists Meeting, May 2012.
Webber, S. A., Siller, G., & Soyer, H. P. (2011). Pigmented spindle cell naevus of Reed: A controversial diagnostic entity in Australia. Australasian Journal of Dermatology, 52(2), 104–108. https://doi.org/10.1111/j.1440-0960.2011.00743.x
Siller, G., Ogbourne, S., Welburn, P., & Ramsey, J. (2009). Discovery and Development Timeline of a Novel Treatment for Actinic Keratosis: PEP005 (Ingenol Mebutate) Gel. The Journal of Investigative Dermatology, 129(12), 2908–2923. https://doi.org/10.1038/jid.2009.333
Siller, G., Rosen, R., Freeman, M., Welburn, P., Katsamas, J., & Ogbourne, S. M. (2010). PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. The Australasian Journal of Dermatology, 51(2), 99–105. https://doi.org/10.1111/j.1440-0960.2010.00626.x
Siller, G., Gebauer, K., Welburn, P., Katsamas, J., & Ogbourne, S. M. (2009). PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australasian Journal of Dermatology, 50(1), 16–22. https://doi.org/10.1111/j.1440-0960.2008.00497.x
Foley, P., Freeman, M., Menter, A., Siller, G., El-Azhary, R. A., Gebauer, K., Lowe, N. J., Jarratt, M. T., Murrell, D. F., Rich, P., Pariser, D. M., Oseroff, A. R., Barnetson, R., Anderson, C., Kossard, S., Gibson, L. E., & Tope, W. D. (2009). Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: Results of two randomized studies. International Journal of Dermatology, 48(11), 1236–1245. https://doi.org/10.1111/j.1365-4632.2008.04022.x
McHugh, A., Siller, G., Williamson, R., & Faulkner, C. (2008). Nodular granulomatous phlebitis: A phlebitic tuberculid. Australasian Journal of Dermatology, 49(4), 220–222. https://doi.org/10.1111/j.1440-0960.2008.00473.x
Wu, J. K., Oh, C., Strutton, G., & Siller, G. (2006). An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. The Australasian Journal of Dermatology, 47(1), 46–48. https://doi.org/10.1111/j.1440-0960.2006.00222.x
Vun, Y., & Siller, G. (2006). Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. The Australasian Journal of Dermatology, 47(3), 169–171. https://doi.org/10.1111/j.1440-0960.2006.00265.x
Har-Shai, Y., Glickman, Y. A., Siller, G., McLeod, R., Topaz, M., Howe, C., Ginzburg, A., Zamir, B., Filo, O., Kenan, G., & Ullmann, Y. (2005). Electrical impedance scanning for melanoma diagnosis: A validation study. Plastic and Reconstructive Surgery, 116(3), 782–790. https://doi.org/10.1097/01.prs.0000176258.52201.22
Freeman, M., Siller, G., Edwards, S., & Amies, M. (2004). Imiquimod 5% cream in the treatment of multiple superficial basal cell carcinoma. Journal of the American Academy of Dermatology, 50(3), P7. https://doi.org/10.1016/j.jaad.2003.10.033
Valery, P. C., Neale, R., Williams, G., Pandeya, N., Siller, G., & Green, A. (2004). The effect of skin examination surveys on the incidence of basal cell carcinoma in a Queensland community sample: a 10-year longitudinal study. The Journal of Investigative Dermatology Symposium Proceedings, 9(2), 148–151. https://doi.org/10.1046/j.1087-0024.2003.09114.x
Wu, J. K., Siller, G., & Whitehead, K. (2003). Treatment of Bowen’s disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australasian Journal of Dermatology, 44(2), 123–125. https://doi.org/10.1046/j.1440-0960.2003.00658.x
Dicker, T., Siller, G., & Saunders, N. (2002). Molecular and cellular biology of basal cell carcinoma. The Australasian Journal of Dermatology, 43(4), 241–246. https://doi.org/10.1046/j.1440-0960.2002.00609.x
Galligan, P., Listwan, P., Siller, G. M., & Rothnagel, J. A. (1998). A novel mutation in the L12 domain of keratin 5 in the Köbner variant of epidermolysis bullosa simplex. Journal of Investigative Dermatology, 111(3), 524–527. https://doi.org/10.1046/j.1523-1747.1998.00308.x
Siller, G. M., Strutton, G. M., Moore, G. A., Kanowski, D. M., & Nedwich, J. A. (1994). Glucagonoma syndrome with increased lactate dehydrogenase isoenzymes: octreotide treatment. The Australasian Journal of Dermatology, 35(1), 11–14. https://doi.org/10.1111/j.1440-0960.1994.tb01792.x
Siller, G. M., & Seymour, G. J. (1994). Kinetics and specificity of nickel hypersensitivity in the murine model. The Australasian Journal of Dermatology, 35(2), 77–81. https://doi.org/10.1111/j.1440-0960.1994.tb00901.x
Siller, G. M., Tod, M. A., & Savage, N. W. (1994). Minocycline-induced oral pigmentation. Journal of the American Academy of Dermatology, 30(2 Pt 2), 350–354. https://doi.org/10.1016/S0190-9622(94)70038-9
